Latest Quarterly Report
Filed: 2026-05-11
Key Insights
- Aura Biosciences conducted multiple equity offerings in Q1 2026, including a follow-on offering (May 4-5, 2026) with common stock and pre-funded warrants, indicating capital raising activity to fund operations and R&D initiatives.
- The company maintains active licensing and collaboration agreements including royalty-bearing patent licenses and exclusive supply agreements with partners like LICOR Inc and Life Technologies, suggesting ongoing monetization of intellectual property and supply chain dependencies.
- Multiple equity compensation plans are active (2018/2021 Stock Options Plan, 2021 Employee Stock Purchase Plan, 2021 Stock Option and Incentive Plan), with RSU and option activity through Q1 2026, reflecting standard employee retention practices but also ongoing dilution.
- The filing shows investments in money market funds and U.S. government securities as of December 31, 2025 and Q1 2026, suggesting the company maintains a conservative cash management strategy with available liquidity reserves.